<DOC>
	<DOCNO>NCT01066104</DOCNO>
	<brief_summary>The investigator research study learn drug call Xolair ( omalizumab ) . The investigator want see effective treatment chronic rhinosinusitis ( CRS ) . Specifically , investigator want see whether Xolair make nasal polyp small less thick , relieve symptom people CRS . Polyps abnormal growth tissue grow line sinus ( inside nose ) . The investigator also want find safe use ( whether cause side effect ) .</brief_summary>
	<brief_title>Subcutaneous Omalizumab Treatment Chronic Rhinosinusitis With Nasal Polyposis</brief_title>
	<detailed_description />
	<mesh_term>Sinusitis</mesh_term>
	<mesh_term>Nasal Polyps</mesh_term>
	<mesh_term>Omalizumab</mesh_term>
	<criteria>Inclusion criterion 1 . Subjects male female 18 year age old . 2 . Females childbearing potential use approve contraception , define use hormonal ( oral , injectable , implantable ) barriermethod contraceptive , intrauterine device , history bilateral tubal ligation . Women undergone total hysterectomy two year postmenopausal also eligible . 3 . Subjects must meet criterion CRS , namely must ( 1 ) least two major criterion ( facial pain/pressure headache , nasal congestion , anterior posterior nasal drainage , hyposmia/anosmia ) least 3 consecutive month ; ( 2 ) abnormal sinus CT scan least two sinus area document within 3 month entry endoscopic evidence disease . 4 . Subjects must bilateral polypoid disease demonstrate either CT endoscopy evidence nasal polyp polypoid mucosa examination least two follow area : right maxillary sinus , leave maxillary sinus , right anterior ethmoid sinus , leave anterior ethmoid sinus plus minimal polyp/polypoid score 4 baseline rhinoscopic examination . ( Nasal polyp define discreet polyp visible middle meatus area . ) 5 . Evidence history positive skin test vitro reactivity perennial aeroallergen . 6 . Subjects must meet study drugdosing table eligibility criterion ( serum IgE level ≥ 30 ≤ 1500 IU/mL body weight ≥ 30 ≤ 150 kg ) . 7 . Subjects must minimum total symptom score 5 ( range score 015 ) baseline . Exclusion criteria 1 . Females pregnant nursing , females childbearing potential use approved contraception , define use hormonal ( oral , injectable , implantable ) barriermethod contraceptive , intrauterine device , history bilateral tubal ligation . 2 . Subjects meet clinical criterion Xolair ( omalizumab ) 3 . Subjects take beta blocker . 4 . Known sensitivity Xolair ( omalizumab ) . 5 . Subjects evidence acute bacterial exacerbation rhinosinusitis require antibiotic therapy manifest gross purulent drainage physical examination untreated air/fluid level sinus CT scan . 6 . Subjects receive antibiotic within 3 week screen visit . 7 . Subjects uncontrolled moderate severe asthma experience recent exacerbation require use systemic steroid burst within 6 week study enrollment . Subjects receive maintenance dose Prednisone 5 mg/day less allow provide dose Prednisone change study . 8 . Subjects history uncontrolled recurrent epistaxis within past 6 week . 9 . Subjects history hypogammaglobulinemia , cystic fibrosis , bronchiectasis , immotile cilium syndrome , systemic granulomatous disease , malignancy ( strong family history malignancy ) , history recent cocaine use . 10 . Cigarette smoke past 3 year . 11 . Subjects serious medical problem , Grade III/IV cardiac problem define New York Heart Association Criteria within 6 month study , severe and/or uncontrolled medical disease ( i.e. , uncontrolled diabetes , chronic renal liver disease , infection HIV active uncontrolled infection ) . Subjects major surgery within 3 month screen visit . 12 . Subjects significant history noncompliance medical regimen inability grant reliable informed consent . 13 . Subjects alcohol drug abuse/dependence within past 3 month . 14 . Subjects persistent abnormality hepatic , renal hematologic function , define follow : total bilirubin , SGOT SGPT &gt; 1.5 x upper limit normal , creatinine &gt; 2.0 x upper limit normal , absolute neutrophil count &lt; 1.5 x 109/L , platelet &lt; 100 x 109/L . 15 . Subjects use oral systemic steroid burst within 6 week study enrollment . 16 . Use investigational agent 30 day prior enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>